ENTRY       D01977                      Drug
NAME        Gefitinib (JP18/USAN/INN);
            Iressa (TN)
PRODUCT     IRESSA (AstraZeneca Pharmaceuticals LP)
  GENERIC   GEFITINIB (Apotex Corp.)
            GEFITINIB (Ingenus Pharmaceuticals)
            GEFITINIB (Natco Pharma USA LLC)
            GEFITINIB (Qilu Pharmaceutical)
            GEFITINIB (Teva Pharmaceuticals)
FORMULA     C22H24ClFN4O3
EXACT_MASS  446.1521
MOL_WEIGHT  446.9024
CLASS       Antineoplastic
             DG01918  Tyrosine kinase inhibitor
              DG01917  Receptor tyrosine kinase inhibitor
               DG03162  EGFR inhibitor
REMARK      Therapeutic category: 4291
            ATC code: L01EB01
            Product: D01977<JP/US>
EFFICACY    Antineoplastic, Receptor tyrosine kinase inhibitor
  DISEASE   Non-small cell lung cancer (EGFR mutation positive) [DS:H00014]
TARGET      EGFR* [HSA_VAR:1956v2] [HSA:1956] [KO:K04361]
  PATHWAY   hsa04010(1956)  MAPK signaling pathway
            hsa04012(1956)  ErbB signaling pathway
            hsa05200(1956)  Pathways in cancer
            hsa05223(1956)  Non-small cell lung cancer
INTERACTION  
STR_MAP     map07045  Antineoplastics - protein kinase inhibitors
OTHER_MAP   map01521  EGFR tyrosine kinase inhibitor resistance
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01E PROTEIN KINASE INHIBITORS
                L01EB Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
                 L01EB01 Gefitinib
                  D01977  Gefitinib (JP18/USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Molecular Target Inhibitors
               Gefitinib
                D01977  Gefitinib (JP18/USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             4  Agents affecting cellular function
              42  Antineoplastics
               429  Miscellaneous
                4291  Other Antitumors
                 D01977  Gefitinib (JP18/USAN/INN)
            Drug groups [BR:br08330]
             Antineoplastic
              DG01918  Tyrosine kinase inhibitor
               DG01917  Receptor tyrosine kinase inhibitor
                DG03162  EGFR inhibitor
                 D01977  Gefitinib
            Drug classes [BR:br08332]
             Antineoplastic
              DG03162  EGFR inhibitor
               D01977  Gefitinib
            Target-based classification of drugs [BR:br08310]
             Protein kinases
              Receptor tyrosine kinases (RTK)
               EGFR family
                EGFR* [HSA_VAR:1956v2]
                 D01977  Gefitinib (JP18/USAN/INN) &lt;JP/US&gt;
            Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
             Chemicals
              D01977  Gefitinib
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D01977
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D01977
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D01977
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D01977
            Pharmacogenomic biomarkers [br08341.html]
             Somatic variations in targeted cancer therapies
              D01977
DBLINKS     CAS: 184475-35-2
            PubChem: 7849039
            ChEBI: 49668
            PDB-CCD: IRE
            LigandBox: D01977
            NIKKAJI: J1.437.124I
ATOM        31
            1   C8x C    14.9262  -11.3780
            2   N5x N    14.9262  -12.7769
            3   C8y C    16.1377  -13.4764
            4   C8y C    17.3492  -12.7769
            5   C8y C    17.3492  -11.3780
            6   N5x N    16.1377  -10.6786
            7   C8x C    18.5607  -13.4764
            8   C8y C    19.7722  -12.7769
            9   C8y C    19.7722  -11.3780
            10  C8x C    18.5607  -10.6786
            11  N1b N    16.1377  -14.8754
            12  O2a O    20.9864  -10.6770
            13  C1a C    22.1998  -11.3776
            14  O2a O    20.9864  -13.4779
            15  C1b C    22.1998  -12.7773
            16  C1b C    23.4120  -13.4764
            17  C1b C    24.6236  -12.7769
            18  N1y N    25.8350  -13.4764
            19  C8y C    17.3499  -15.5752
            20  C8x C    17.3499  -16.9737
            21  C8y C    18.5614  -17.6732
            22  C8y C    19.7728  -16.9737
            23  C8x C    19.7728  -15.5752
            24  C8x C    18.5614  -14.8758
            25  X   F    20.9866  -17.6744
            26  X   Cl   18.5614  -19.0779
            27  C1x C    25.8349  -14.8826
            28  C1x C    27.0470  -15.5825
            29  O2x O    28.2592  -14.8827
            30  C1x C    28.2593  -13.4765
            31  C1x C    27.0472  -12.7766
BOND        34
            1     1   2 1
            2     2   3 2
            3     3   4 1
            4     4   5 1
            5     5   6 1
            6     1   6 2
            7     4   7 2
            8     7   8 1
            9     8   9 2
            10    9  10 1
            11    5  10 2
            12    3  11 1
            13    9  12 1
            14   12  13 1
            15    8  14 1
            16   14  15 1
            17   15  16 1
            18   16  17 1
            19   17  18 1
            20   11  19 1
            21   19  20 2
            22   20  21 1
            23   21  22 2
            24   22  23 1
            25   23  24 2
            26   19  24 1
            27   22  25 1
            28   21  26 1
            29   18  27 1
            30   27  28 1
            31   28  29 1
            32   29  30 1
            33   30  31 1
            34   18  31 1
///
